论文部分内容阅读
[目的]观察康艾注射液联合西药治疗失代偿期乙肝肝硬化疗效。[方法]使用随机平行对照方法,将41例住院患者按随机平行对照方法方法随机分为两组。对照组22例核苷(酸)类似物抗病毒,甘草甜素制剂、多烯磷脂酰胆碱等保肝。治疗组18例康艾注射液30m L+5%葡萄糖250m L,1次/d,静滴;西药治疗同对照组。连续治疗30d为1疗程。观测临床症状、肝功能(TBil、ALB、ALT、AST)、血常规(WBC)和体力状况(KPS评分)、不良反应。治疗1疗程,判定疗效。[结果]TBil、ALT、AST两组均明显改善(P<0.05,P<0.01),组间无明显差异(P>0.05);ALB治疗组明显升高(P<0.05),对照组无明显变化(P>0.05),组间差异显著(P<0.01)。WBC、PLT均无明显变化(P>0.05)。KPS评分两组均明显改善(P<0.01),治疗组改善优于对照组(P<0.01)。[结论]康艾注射液联合西药治疗失代偿期乙肝肝硬化,疗效满意,无严重不良反应,值得推广。
[Objective] To observe the curative effect of Kangai injection combined with western medicine on decompensated hepatitis B cirrhosis. [Method] Randomized parallel method was used to divide 41 inpatients randomly into two groups according to the method of randomized parallel control. Control group, 22 cases of nucleoside (acid) analog anti-virus, glycyrrhizin preparations, polyene phosphatidylcholine and other liver. The treatment group, 18 cases of Kang Ai injection 30m L + 5% glucose 250m L, 1 / d, intravenous infusion; Western medicine treatment with the control group. Continuous treatment of 30d for a course of treatment. Clinical symptoms, liver function (TBil, ALB, ALT, AST), blood routine (WBC) and physical status (KPS score) were observed. Adverse reactions were observed. Treatment of a course of treatment to determine the efficacy. [Results] The levels of TBil, ALT and AST in both groups were significantly improved (P <0.05, P <0.01), there was no significant difference between the two groups (P> 0.05) (P> 0.05), the difference between groups was significant (P <0.01). WBC, PLT had no significant change (P> 0.05). KPS scores were significantly improved in both groups (P <0.01), the treatment group improved better than the control group (P <0.01). [Conclusion] Kangai injection combined with Western medicine in the treatment of decompensated hepatitis B cirrhosis has satisfactory curative effect and no serious adverse reactions, which deserves promotion.